Abstract

The present invention relates to heterocyclic derivatives of formula (I)



(I)

wherein

R represents halogen, C_{1-4} alkyl, cyano, C_{1-4} alkoxy, trifluoromethyl or trifluoromethoxy;

R_1 represents a 5 or 6 membered heteroaryl group, in which the 5-membered heteroaryl group contains at least one heteroatom selected from oxygen, sulphur or nitrogen and the 6-membered heteroaryl group contains from 1 to 3 nitrogen atoms, or R_1 represents a 4, 5 or 6 membered heterocyclic group, wherein saids 5 or 6 membered heteroaryl or the 4, 5 or 6 membered heterocyclic group may optionally be substituted by one to three substituents, which may be the same or different, selected from $(CH_2)_pR_6$, wherein p is zero or an integer from 1 to 4 and R_6 is selected from:

halogen,

C_{1-4}alkoxy,

C_{1-4}alkyl,

C_{3-7}cycloalkyl,

C_{1-4} alkyl optionally substituted by halogen, cyano or C_{1-4} alkoxy,

hydroxy,

cyano,

nitro,

trifluoromethyl,

carboxy,

$NH(C_{1-4}$ alkyl),

$N(C_{1-4}$ alkyl$)_2$

$NH(C_{3-7}$ cycloalkyl),

$N(C_{1-4}$ alkyl)(C_{3-7} cycloalkyl);

$NH(C_{1-4}alkylOC_{1-4}alkoxy)$,

$OC(O)NR_7R_8$,

$NR_8C(O)$ R_7 or

$C(O)NR_7R_8$;

R_2 represents hydrogen, or C_{1-4} alkyl ;

R_3 and R_4 independently represent hydrogen, C_{1-4} alkyl or R_3 together with R_4 represents C_{3-7} cycloalkyl;

R_5 represents trifluoromethyl, $S(O)_qC_{1-4}$ alkyl, C_{1-4} alkyl, C_{1-4} alkoxy, trifluoromethoxy, halogen or cyano;

R_7 and R_8 independently represent hydrogen, C_{1-4} alkyl or C_{3-7} cycloalkyl;

L is a single or a double bond;

n is an integer from 1 to 3;

m is zero or an integer from 1 to 3;

q is zero or an integer from 1 to 2;

provided that

a) when L is a double bond, R_1 is not an optionally substituted 5 or 6 membered heteroaryl group, in which the 5-membered heteroaryl group contains at least one heteroatom selected from oxygen, sulphur or nitrogen and the 6-membered heteroaryl group contains from 1 to 3 nitrogen atoms;

b) the group R_1 is linked to the carbon atom shown as * via a carbon atom; and

c) when the heteroatom contained in the group R_1 is substituted, p is not zero;

and pharmaceutically acceptable salts and solvates thereof; process for their preparation and their use in the treatment of conditions mediated by tachykinins and/or by selective inhibition of serotonin reuptake transporter protein.